|Project||Cost||Real world outcome||Outcome estimates||Economic value in Western terms||Leverage Factor|
|Malaria prevention and Artemesinin Combination Therapy treatment package (Solutions to the World's Biggest Problems, Bjorn Lomborg, 2007, pp. 325)||$500m/yr||500k mostly child lives/yr||-||$1.3t||2,600|
|Indoor residual spraying (Priorities in Healthcare, The World Bank, 2006, pp. 75)||$5-18||1 DALY saved||-||$90k||5,000 - 18,000|
|Indoor residual spraying (Disease Control Priorities Project reports on the cost effectiveness of intervention)||$9-24||1 DALY saved||-||$90k||4,000 - 10,000|
|Intermitent prophylactic treatment during pregnancy (Disease Control Priorities Project reports on the cost effectiveness of intervention)||$2-11||1 DALY saved||Sub-Saharan Africa||$90k||8,000 - 45,000|
Prophylactic treatment during pregnancy is considered a special case, and so won't be incorporated into the overall Leverage Factor.
4,000 - 20,000